EUVIMEDEUVIMED entdecken
Open Access

Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis

Chuan Long, Yingding Ruan, Aiming Yang, Suwei Xu, Jianwei Han

Oncology Letters · 27.10.2026 · 32 (6) · 1-13

DOI: 10.3892/ol.2026.15921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 27.10.2026. Verfasst von Chuan Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First People's Hospital of Jiande, Jiande, Zhejiang 311600, P.R. China. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First-line chemoimmunotherapy is currently a standard treatment for extensive-stage small cell lung cancer (ES-SCLC), but the value of immune checkpoint inhibitor (ICI)-based subsequent treatment after progression remains uncertain. The present meta-analysis assessed the efficacy and safety of ICI-based vs. non-immunotherapy subsequent treatment after progression on first-line chemoimmunotherapy. The present systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement. The PubMed, Embase, Web of Science Core Collection, Scopus and Cochrane Library databases were searched from their respective dates of inception to May 8, 2026. Comparative studies evaluating ICI-based vs. non-immunotherapy subsequent treatment after progression on first-line chemoimmunotherapy in ES-SCLC were eligible for inclusion. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included objective response rate (ORR), disease control rate (DCR) and grade ≥3 adverse events (AEs) or treatment-related AEs (TRAEs). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were pooled using random-effects models. A total of 10 non-randomized comparative studies, including nine retrospective clinical real-world cohorts and one retrospective translational cohort analysis, were included. Among these, six studies contributed to the primary OS and PFS meta-analyses, whereas the remaining four were included in qualitative synthesis or sensitivity analyses because of incomplete eligibility alignment or non-poolable estimates. Compared with non-immunotherapy subsequent treatment, ICI-based subsequent treatment was associated with longer OS (HR, 0.62; 95% CI, 0.51-0.74; P

Schlagwörter

Stichwörter der Autor:innen

ES-SCLCICIchemoimmunotherapymeta-analysistreatment beyond progression

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First People's Hospital of Jiande, Jiande, Zhejiang 311600, P.R. China.

Zitieren

APA

Long, C., Ruan, Y., Yang, A., Xu, S., & Han, J. (2026). Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis. Oncology Letters, 32(6), 1-13. https://doi.org/10.3892/ol.2026.15921

Vancouver

Long C, Ruan Y, Yang A, Xu S, Han J. Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis. Oncology Letters. 2026;32(6):1-13. doi:10.3892/ol.2026.15921

BibTeX
@article{Long2026,
  author = {Long, Chuan and Ruan, Yingding and Yang, Aiming and Xu, Suwei and Han, Jianwei},
  title = {Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis},
  journal = {Oncology Letters},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1--13},
  doi = {10.3892/ol.2026.15921}
}
Kostenlos starten →